This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 153 entries.
The Motley Fool’s Aaron Teboneras featured Botanix Pharmaceuticals as a top stock pick in an article today. “At the time of writing, the Botanix share price is trading at 10 cents, up 7.5% for the day. With a market capitalisation of $97 million, if the company can perform to market expectations, its share price will […]
Two US lawmakers have introduced a bipartisan bill to create a new payment model to encourage drug developers to develop new classes of antibiotics. It’s called the PASTEUR Act, which will facilitate upfront payments to companies in exchange for unlimited access to their antibiotics. In turn, drug makers can recover their costs and turn a […]
Botanix Pharmaceuticals Executive Director, Matt Callahan, spoke with Stockhead about the global threat of antimicrobial resistance yesterday: “The alarm bells have been going off the last five years (on antimicrobial resistance), but no one’s really believed that the global economy could be stopped and millions and millions of deaths could be caused by some kind […]
Botanix welcomes, wholeheartedly, today’s news from MTPConnect announcing the formation of an Australian-first network to address the impact of antimicrobial resistance (AMR) on human health. The Australian Antimicrobial Resistance network – AAMRNet – was launched in response to urgent recommendations in a new report by MTPConnect, ‘Fighting Superbugs: A Report on the Inaugural Meeting of Australia’s Antimicrobial […]
The emergence of antimicrobial resistance (AMR), including drug-resistant bacteria, or “superbugs”, pose far greater risks to human health than Covid-19, threatening to put modern medicine “back into the dark ages”, an Australian scientist has warned, ahead of a three-year study into drug-resistant bacteria in Fiji. “If you thought Covid was bad, you don’t want anti-microbial […]
Experts have warned that the COVID-19 pandemic might just be one in a series of increasingly frequent viral outbreaks, as the human species enters what they describe as “a pandemic era”. Anthony Fauci, leading US immunologist and director of the National Institute of Allergy and Infectious Diseases (NIAID), and David Morens, a medical epidemiologist at […]
‘After colonising the skin explants with methicillin-resistant staphylococcus aureus (MRSA), the “Human Skin Study” found that BTX 1801 successfully eliminated the so-called superbug within 24 hours.’ Read the full article on Stockhead here.
Cannabinoid skincare company Botanix (BOT) has proven its BTX 1801 compound’s ability to treat and prevent surgical site infections (SSIs). ‘The company has released encouraging results from a study testing the formulation’s ability to eliminate methicillin-resistant Staphylococcus aureus — known as MRSA or Golden Staph — from infected human skin explants. Read the full article […]
Botanix Pharmaceuticals (ASX:BOT) has today shared a market update and new data pertaining to the BTX 1801 antimicrobial program, which is currently being studied as part of a Phase 2a clinical trial in Perth. The new data demonstrates BTX 1801 eliminates methicillin-resistant Staphylococcus aureus (‘MRSA’ or ‘Golden Staph’) from human skin explants infected with […]
Botanix Pharmaceuticals released promising new clinical data for its BTX 1801 antimicrobial platform and a supporting presentation today. The results demonstrate how synthetic cannabidiol kills resistant bacteria quickly and effectively – specifically Staphylococcus aureus (‘S.aureus’ or‘MRSA’ or ‘Golden Staph’), which greatly increases the risks of serious and life-threatening infections following surgery when it is carried […]
